Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Microarrays].

M-O Grimm1, F H Hartmann, W A Schulz

  • 1Urologische Klinik der Heinrich-Heine-Universität Düsseldorf. marc-oliver.grimm@uni-duesseldorf.de

Der Urologe. Ausg. A
|May 13, 2004
PubMed
Summary
This summary is machine-generated.

Microarray gene expression profiling reveals molecular signatures in prostate cancer. These signatures aid in diagnosing tumors, predicting progression, and understanding hormone-refractory disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure.

ESMO open·2025
Same author

Larcher et al. The OpeRa trial: the active role of the patient in the clinical decision-making process and surgical planning.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Profiling autoantibodies at baseline and during immune checkpoint inhibitor therapy of renal cell carcinoma patients-exploratory results from TITAN-RCC.

ESMO open·2025
Same author

Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
Same journal

Der Urologe. Ausg. A·2022
See all related articles

Area of Science:

  • Genomics
  • Molecular Biology
  • Bioinformatics

Context:

  • Microarrays enable high-throughput gene expression analysis, crucial for understanding complex diseases like cancer.
  • Gene expression profiling identifies distinct molecular signatures in various tissues and cell types.
  • Tumor-specific molecular signatures correlate with disease characteristics such as stage, grade, and treatment response.

Purpose:

  • To investigate the utility of gene expression profiling in characterizing prostate cancer.
  • To identify molecular signatures associated with prostate cancer diagnosis, progression, and hormone refractoriness.

Summary:

  • Microarray analysis of gene expression profiles provides insights into the molecular basis of prostate cancer.
  • Identified molecular signatures include specific genes like hepsin and alpha-methyl-acryl-CoA-racemase, potentially serving as diagnostic markers.

Related Experiment Videos

  • Expression patterns of steroid biosynthesis enzymes and the androgen receptor are linked to hormone-refractory prostate cancer.

    • Impact:

    • Gene expression profiling offers a powerful tool for characterizing prostate tumors and their alterations.
    • Identified molecular signatures can improve diagnostic accuracy and prognostic prediction in prostate cancer.
    • This approach contributes to a deeper understanding of prostate cancer biology, particularly in advanced or refractory stages.